Patient disposition from EXPLORER and PATHFINDER studies.^aEighty-six patients in EXPLORER include 16 non-AdvSM and 1 with CMML by central diagnosis. ^bSmPC population included in supplemental Appendix. ^cOne patient enrolled who initiated 200 mg QD in EXPLORER with a local diagnosis of AdvSM was centrally adjudicated to have indolent SM. SmPC, summary of medicinal product characteristics.